Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

Antón Aparicio, Luis Miguel

Statistics

Statistics

View Usage Statistics

Identifiers

Identifiers

URI: http://hdl.handle.net/20.500.11940/8460

PMID: 24536060

DOI: 10.1158/1078-0432.ccr-13-1869

ISSN: 1078-0432

Full record

Services

Services

RIS

Mendeley

Linksolver

Date issued

2014

Journal title

CLINICAL CANCER RESEARCH

Type of content

Artigo